Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
71.96 USD | +1.20% | +3.63% | +8.82% |
Apr. 15 | Morgan Stanley Ups Price Target on MetLife to $82 From $80 | MT |
Apr. 11 | Wells Fargo Adjusts MetLife's Price Target to $86 From $83, Maintains Overweight Rating | MT |
Summary
- The company presents an interesting fundamental situation from a short-term investment perspective.
- The company has a good ESG score relative to its sector, according to Refinitiv.
Strengths
- The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
- The equity is one of the most attractive in the market with regard to earnings multiple-based valuation.
- Given the positive cash flows generated by its business, the company's valuation level is an asset.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- Considering the small differences between the analysts' various estimates, the group's business visibility is good.
Weaknesses
- With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- One of the major weak points of the company is its financial situation.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Life & Health Insurance
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+8.82% | 52.03B | B+ | ||
+16.41% | 80.39B | B- | ||
+1.24% | 48.06B | B | ||
+9.77% | 42.17B | B+ | ||
+7.48% | 40.06B | B+ | ||
+19.18% | 37.62B | B | ||
+2.85% | 29.99B | B | ||
-8.39% | 27.31B | B- | ||
-17.11% | 24.85B | A- | ||
+5.79% | 21.75B | A |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- MET Stock
- Ratings MetLife, Inc.